

Transforming Gynecologic Health

Aspira Women's Health is a bio-analytical company focused on the development and commercialization of women's health diagnostic tools for gynecologic diseases to improve health outcomes for all women. Our blood tests use advanced, proprietary algorithms based on nearly two decades of research and clinical experience.

OvaSuiteSM is the company's portfolio of multi-marker ovarian cancer blood tests, ordered over 194,000 times, to assist healthcare providers in making informed treatment decisions for the 1.2 to 1.5 million American women diagnosed with adnexal masses each year. The domestic market opportunity for OvaSuite is estimated at \$600M to \$715M.

EndoCheckSM is our first-generation non-invasive protein-based blood test to aid in the detection of endometriosis. EndoCheck is currently in development.

Investment Highlights

- Revenue-generating company with a portfolio of proprietary risk assessment assays targeting ovarian cancer, collectively called OvaSuite
- Experienced management team with proven track record of success
- Broad managed care coverage (Ova1Plus[®] and OvaWatchSM Medicare reimbursement - \$897)
- Strong IP and technology protection
- Transformative pipeline opportunities including an upcoming launch of EndoCheck and expansion of OvaWatch for longitudinal monitoring

Our OvaSuite Products



OvaWatch, a lab-developed test performed on an FDA approved platform with a 99% Negative Predictive Value, assists in the initial clinical assessment of ovarian malignancy risk in patients with adnexal masses not planned for surgical intervention.



Ova1Plus combines FDA-cleared blood tests, Ova1[®], and Overa[®], to assess risk of ovarian malignancy in women with adnexal masses planned for surgery.

Recent Developments

28 Nov 2023

Aspira Women's Health Secured Reimbursement for Ova1Plus from CA Medi-Cal at \$897

27 Nov 2023

Aspira Women's Health Received Final Crosswalk Pricing Determination from CMS

9 Nov 2023

Aspira Women's Health Announced CMS Proposed Rule to Crosswalk Rate of \$897

25 Oct 2023

Aspira Women's Health Inc. Saw Poster on its miRNA-based Ovarian Cancer Test Presented at the AACR Special Conference in Cancer Research

23 Oct 2023

Aspira Women's Health Inc. Established a New Clinical Advisory Board

11 Sept 2023

Aspira Women's Health, Inc. Announced Dr. Jody Berry as New Chief Scientific Officer

Fast Facts

Ticker (Exchange)	AWH (NASDAQ)
Stock Price <small>(as of 9/30/23)</small>	\$5.36
Market Cap <small>(as of 9/30/23)</small>	\$55.1M
Outstanding Shares <small>(as of 9/30/23)</small>	10.3M
52-Week Range	\$2.31-\$9.60
Avg. Daily Volume	34,246
Headquarters	Austin, TX
Fiscal Year End	December 31
Cash* Available <small>(as of 9/30/23)</small>	\$5.4M
3Q23 Product Revenues	
In Millions	\$2.2
YoY Growth	9%

*incl cash, cash equivalents and restricted cash

Equity Coverage Analysts

William Blair Andrew Brackmann, CFA	Alliance Global Partners Ben Haynor, CFA
Water Tower Research Sally Yanchus	Cantor Fitzgerald Ross Osborn, CFA

Executive Officers

Nicole Sandford
CEO, President & Board Member

Dr. Torsten Hombeck
Chief Financial Officer

Dr. Jody Berry
Chief Scientific Officer

Minh Hoang Merchant
General Counsel, CCO & Corporate Secretary

Contact

Aspira Women's Health, Inc.
Corporate Headquarters

3 Enterprise Drive, #220
Shelton CT, 06484

Phone: (844) 277-4721

www.aspirawh.com